Last Price
4.82
Today's Change
-0.05 (1.02%)
Day's Change
4.80 - 4.94
Trading Volume
23,308
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Shane J. Schaffer Pharm.D. Dr. Shane J. Schaffer Pharm.D.
Full Time Employees: 13 13
IPO Date: 2021-12-08 2021-12-08
CIK: 0001862150 0001862150
ISIN: US17248W2044 US17248W2044
CUSIP: 17248W105 17248W105
Beta: -0.93 -0.93
Last Dividend: 0.00 0.00
Dcf Diff: 8.28 8.28
Dcf: -3.41 -3.41
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.